On the public citation graph
First‐in‐Human Study With the Inhaled TLR9 Oligonucleotide Agonist AZD1419 Results in Interferon Responses in the Lung, and Is Safe and Well‐Tolerated
0 signed · 55 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/cpt.157openalex-snapshot
Early clinical evaluation of the intranasal TLR7 agonist GSK2245035: Use of translational biomarkers to guide dosing and confirm target engagement
inferredcites →https://doi.org/10.1006/rtph.1997.1099openalex-snapshot
Considerations for Toxicology Studies of Respiratory Drug Products
inferredcites →https://doi.org/10.1007/s00011-015-0873-2openalex-snapshot
Biological effects and clinical efficacy of a topical Toll-like receptor 7 agonist in seasonal allergic rhinitis: a parallel group controlled phase IIa study
inferredcites →https://doi.org/10.1016/j.rmed.2015.11.002openalex-snapshot
Achieving asthma control with ICS/LABA: A review of strategies for asthma management and prevention
inferredcites →https://doi.org/10.1038/clpt.2011.60openalex-snapshot
The Innate Immune Response, Clinical Outcomes, and Ex Vivo HCV Antiviral Efficacy of a TLR7 Agonist (PF-4878691)
inferredcites →https://doi.org/10.1038/nm.2731openalex-snapshot
Innate and adaptive immune responses in asthma
inferredcites →https://doi.org/10.1056/nejmoa0808991openalex-snapshot
Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
inferredcites →https://doi.org/10.1056/nejmoa1304048openalex-snapshot
Dupilumab in Persistent Asthma with Elevated Eosinophil Levels
inferredcites →https://doi.org/10.1089/dna.2005.24.63openalex-snapshot
Superior Activity of the Type C Class of ISS In Vitro and In Vivo Across Multiple Species
inferredcites →https://doi.org/10.1089/oli.1.2000.10.359openalex-snapshot
Pharmacokinetic and Toxicity Profile of a Phosphorothioate Oligonucleotide Following Inhalation Delivery to Lung in Mice
inferredcites →https://doi.org/10.1124/pr.109.001073openalex-snapshot
Therapeutic Targeting of Toll-Like Receptors for Infectious and Inflammatory Diseases and Cancer
inferredcites →https://doi.org/10.1136/bmjresp-2015-000113openalex-snapshot
Tolerability in man following inhalation dosing of the selective TLR7 agonist, AZD8848
inferredcites →https://doi.org/10.1136/thoraxjnl-2013-204605openalex-snapshot
A limited CpG-containing oligodeoxynucleotide therapy regimen induces sustained suppression of allergic airway inflammation in mice
inferredcites →https://doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a4184openalex-snapshot
The Effects Of The Novel Toll-Like Receptor 7 (TLR7) Agonist AZD8848 On Allergen-Induced Responses In Patients With Mild Asthma
inferredcites →https://doi.org/10.1164/rccm.200601-057ocopenalex-snapshot
Immunostimulatory Sequences Regulate Interferon-inducible Genes but not Allergic Airway Responses
inferredcites →https://doi.org/10.1164/rccm.201504-0763ppopenalex-snapshot
Evolving Concepts of Asthma
inferredcites →https://doi.org/10.1172/jci38294openalex-snapshot
CpG-containing immunostimulatory DNA sequences elicit TNF-α–dependent toxicity in rodents but not in humans
inferredcites →https://doi.org/10.1517/13543784.2011.583237openalex-snapshot
VTX-1463, a novel TLR8 agonist for the treatment of allergic rhinitis
inferredcites →https://doi.org/10.2147/jaa.s78049openalex-snapshot
Benralizumab: a unique IL-5 inhibitor for severe asthma
inferredcites →https://doi.org/10.3109/01480545.2011.648327openalex-snapshot
Regulatory toxicology considerations for the development of inhaled pharmaceuticals
inferredcites →https://doi.org/10.3109/08958378.2014.907587openalex-snapshot
Local and systemic tolerability of a 2′O-methoxyethyl antisense oligonucleotide targeting interleukin-4 receptor-α delivery by inhalation in mouse and monkey
inferredcites →https://doi.org/10.4049/jimmunol.1200780openalex-snapshot
TLR7 Stimulation of APCs Results in Inhibition of IL-5 through Type I IFN and Notch Signaling Pathways in Human Peripheral Blood Mononuclear Cells
inferredcites →https://doi.org/10.4049/jimmunol.161.12.7054openalex-snapshot
Immunostimulatory DNA Sequences Inhibit IL-5, Eosinophilic Inflammation, and Airway Hyperresponsiveness in Mice
inferredcites →https://doi.org/10.4187/respcare.03200openalex-snapshot
Asthma and Adherence to Inhaled Corticosteroids: Current Status and Future Perspectives
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.1002/med.21553openalex-snapshot
Recent clinical trends in Toll‐like receptor targeting therapeutics
inferred← citeshttps://doi.org/10.1007/978-1-0716-2010-6_25openalex-snapshot
Preclinical Safety Assessment of Therapeutic Oligonucleotides
inferred← citeshttps://doi.org/10.1016/b978-0-08-102723-3.00008-1openalex-snapshot
Pathogen Recognition Receptors and the Lung
inferred← citeshttps://doi.org/10.1016/b978-0-12-816417-4.00006-8openalex-snapshot
Exacerbations of chronic respiratory diseases
inferred← citeshttps://doi.org/10.1016/bs.apcsb.2019.09.001openalex-snapshot
Pattern recognition receptors as potential drug targets in inflammatory disorders
inferred← citeshttps://doi.org/10.1016/bs.pmch.2022.04.001openalex-snapshot
Advances in the design of new types of inhaled medicines
inferred← citeshttps://doi.org/10.1016/j.addr.2023.114831openalex-snapshot
Aerosol pulmonary immune engineering
inferred← citeshttps://doi.org/10.1016/j.bmcl.2021.128293openalex-snapshot
Modulators of immunoregulatory exonucleases PLD3 and PLD4 identified by high-throughput screen
inferred← citeshttps://doi.org/10.1016/j.heliyon.2025.e42226openalex-snapshot
Toll-like receptors in atopic dermatitis: pathogenesis and therapeutic implications
inferred← citeshttps://doi.org/10.1016/j.immuni.2020.04.004openalex-snapshot
Nucleic Acid Sensors as Therapeutic Targets for Human Disease
inferred← citeshttps://doi.org/10.1016/j.intimp.2018.11.019openalex-snapshot
Preclinical development of the TLR9 agonist DV281 as an inhaled aerosolized immunotherapeutic for lung cancer: Pharmacological profile in mice, non-human primates, and human primary cells
inferred← citeshttps://doi.org/10.1016/j.jconrel.2021.08.010openalex-snapshot
Recent trends of NFκB decoy oligodeoxynucleotide-based nanotherapeutics in lung diseases
inferred← citeshttps://doi.org/10.1016/j.rechem.2024.101349openalex-snapshot
Discovery of PLD4 modulators by high-throughput screening and kinetic analysis
inferred← citeshttps://doi.org/10.1038/s41584-020-00544-4openalex-snapshot
Toll-like receptor signalling in B cells during systemic lupus erythematosus
inferred← citeshttps://doi.org/10.1039/9781788015714-00474openalex-snapshot
Preclinical and Clinical Drug-metabolism, Pharmacokinetics and Safety of Therapeutic Oligonucleotides
inferred← citeshttps://doi.org/10.1111/jcmm.18554openalex-snapshot
Microglial modulation as a therapeutic strategy in Alzheimer's disease: Focus on microglial preconditioning approaches
inferred← citeshttps://doi.org/10.1158/0008-5472.can-18-0729openalex-snapshot
Inhaled TLR9 Agonist Renders Lung Tumors Permissive to PD-1 Blockade by Promoting Optimal CD4+ and CD8+ T-cell Interplay
inferred← citeshttps://doi.org/10.1158/1078-0432.c.6530504openalex-snapshot
Data from A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non–small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1158/1078-0432.c.6530504.v1openalex-snapshot
Data from A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non–small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-21-0263openalex-snapshot
A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non–small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1159/000494463openalex-snapshot
The Role of Toll-Like Receptors in the Production of Cytokines by Human Lung Macrophages
inferred← citeshttps://doi.org/10.1164/rccm.202001-0133ocopenalex-snapshot
A Phase 2a, Double-Blind, Placebo-controlled Randomized Trial of Inhaled TLR9 Agonist AZD1419 in Asthma
inferred← citeshttps://doi.org/10.1186/s11658-025-00834-3openalex-snapshot
The neuro-immune insights of itch: peripheral mechanisms and central glial contributions
inferred← citeshttps://doi.org/10.1360/csb-2025-0655openalex-snapshot
Changes in the expression of TLR9 in PBMCs and pulmonary macrophages during allergic rhinitis and asthma attacks
inferred← citeshttps://doi.org/10.2147/jir.s546218openalex-snapshot
Adjuvant Strategies to Improve the Efficacy of Allergen Immunotherapy
inferred← citeshttps://doi.org/10.3389/fmolb.2023.1204025openalex-snapshot
When the allergy alarm bells toll: The role of Toll-like receptors in allergic diseases and treatment
inferred← citeshttps://doi.org/10.3389/fphar.2020.601685openalex-snapshot
TLR9 and COVID-19: A Multidisciplinary Theory of a Multifaceted Therapeutic Target
inferred← citeshttps://doi.org/10.3390/pharmaceutics11090441openalex-snapshot
Toll-Like Receptors and Relevant Emerging Therapeutics with Reference to Delivery Methods
inferred← citeshttps://doi.org/10.52225/narra.v2i3.92openalex-snapshot
A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.